Generex Biotechnology Corp. (OTC:GNBT) announced that it entered into a securities purchase agreement with certain institutional investors on Jan. 24, 2011. The investors agreed to purchase up to $6 million of shares of the company’s …
Generex Biotechnology Corporation today announced that its subsidiary, Hema Diagnostic Systems LLC , has received an initial order for its Rapid 1-2-3® Hema HIV EXPRESS® from Diagnostiko Ltda.
WORCESTER, Mass., Sept. 1, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT), the …
26.74 13.61 ... ... DryShips DRYS 7.10 +.02 91.53 2.72 +.3 -92.1 FifthThird FITB 7.25 +.12 .04 21.00 1.01 +1.7 -57.6 GenBiotc h GNBT .75 -.06 1.14 .08 -7.4 -24.3 Intel INTC 15.92 ... .56 24.75 12.05 ... -31.0 Microsoft MSFT 22.05 -.09 …
WORCESTER, Mass., Sept. 2, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (Nasdaq:GNBT) today announced the engagement of Dr. George E. Peoples, Jr., M.D., F.A.C.S. as a consultant to the …
It wasn't hard for investors to find gains in 2013. This year is different – unless you're invested in one or more companies on this growing hot penny stocks list boasting huge year-to-date gains. Leading the pack of 2014's surging low-priced …
Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, …
Up last 7 days N/A N/A N/A N/A Up last 30 days N/A N/A N/A N/A Down last 30 days N/A N/A N/A N/A Down last 90 days N/A N/A N/A N/A Next 5 years (per annum) N/A N/A N/A 0.10 Past 5 years (per annum) N/A N/A N/A N/A
Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, …
Up last 7 days N/A N/A N/A N/A Up last 30 days N/A N/A N/A N/A Down last 30 days N/A N/A N/A N/A Down last 90 days N/A N/A N/A N/A Next 5 years (per annum) N/A N/A N/A 0.10 Past 5 years (per annum) N/A N/A N/A N/A